Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 115Breast Neoplasms 113Ovarian Neoplasms 71Triple Negative Breast Neoplasms 56Fallopian Tube Neoplasms 42Endometrial Neoplasms 42Squamous Cell Carcinoma of Head and Neck 39Lung Neoplasms 38Neoplasm Metastasis 35Stomach Neoplasms 28Neoplasms 28Parkinson Disease 4, Autosomal Dominant Lewy Body 27Esophageal Neoplasms 22Esophageal Squamous Cell Carcinoma 21Head and Neck Neoplasms 16Carcinoma 16Uterine Cervical Neoplasms 15Carcinoma, Ovarian Epithelial 15Colorectal Neoplasms 14Carcinoma, Squamous Cell 11Adenocarcinoma 10Small Cell Lung Carcinoma 9Adenocarcinoma Of Esophagus 9Peritoneal Neoplasms 8Oropharyngeal Neoplasms 8Melanoma 8Carcinoma, Transitional Cell 8Urinary Bladder Neoplasms 7Pancreatic Neoplasms 7Mouth Neoplasms 7

Interventions

Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Platinum-resistant Recurrent Ovarian Cancer × Paclitaxel × 1 year × Clear all
NCT06434610 2026-05-05

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Shanghai Jiaolian Drug Research and Development Co., Ltd

Phase 2 Recruiting
90 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡